Chrysalis BioTechnology Presents at Southwest Bio Conference
December 10 2003 - 9:00AM
PR Newswire (US)
Chrysalis BioTechnology Presents at Southwest Bio Conference
Chrysalin(R) Continues Advancement in Multiple Indications
GALVESTON, Texas, Dec. 10 /PRNewswire/ -- Chrysalis BioTechnology,
Inc., today presented a business and product development update at
the fourth annual Southwest Bio Venture Conference & Symposium
in Houston. Dennis McWilliams, Chief Operating Officer, reported
that the Company's patented lead drug candidate, Chrysalin(R), is
progressing in clinical trials for the treatment of bone fractures
and diabetic ulcers, and that the Company has added additional
peptide drug candidates to its product development pipeline. "Phase
3 evaluation of Chrysalin used to accelerate the healing of bone
fractures has progressed under the direction of our corporate
partner, OrthoLogic Corporation (NASDAQ:OLGC)," stated McWilliams.
"OrthoLogic is focused on commercializing several potential
orthopedic indications of Chrysalin, including bone fractures,
spine fusion, and cartilage." In addition to the products for
orthopedics, Chrysalis has retained the rights to active Chrysalin
programs in chronic diabetic ulcers, currently in Phase 2, and
additional programs in dental bone regeneration and cardiovascular
repair. Beyond the Chrysalin peptide, the Company has added two
novel patented peptide based drug candidates for infection control
and cancer metastasis. All of these potential products address
sizeable markets and represent additional partnering opportunities.
Chrysalin, also known as TP508, is a 23-amino acid synthetic
peptide that represents a portion of the human enzyme thrombin, a
naturally occurring molecule that plays a critical role in the
body's ability to heal its own wounds, including the initiation of
blood clotting and tissue repair. Chrysalin interacts directly with
selected thrombin receptors on cells involved in tissue repair,
triggering the release of growth factors and other wound healing
signals, without affecting blood clotting. Chrysalis BioTechnology,
Inc., is a privately held biopharmaceutical company located in
Texas developing synthetic peptide compounds for tissue repair and
regeneration. The Company's lead compound, Chrysalin(R), is in a
Phase 3 clinical trial for bone fracture healing and a Phase 2
trial for spine fusion, each under an exclusive license agreement
with OrthoLogic Corporation. The Company intends to initiate a
Phase 2 clinical trial for the treatment of chronic diabetic ulcers
during 2004. For more information visit the Chrysalis BioTechnology
website at http://www.chrysalisbio.com/. This release was issued
through Major Newswire (http://www.majornewswire.com/) DATASOURCE:
Chrysalis BioTechnology, Inc. CONTACT: Dennis McWilliams of
Chrysalis BioTechnology, Inc., +1-409-750-9251 or +1-409-771-9059
Web site: http://www.majornewswire.com/ Web site:
http://www.chrysalisbio.com/
Copyright
Orthologic (MM) (NASDAQ:OLGC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Orthologic (MM) (NASDAQ:OLGC)
Historical Stock Chart
From Aug 2023 to Aug 2024